Signal
Biotechs Excalipoint and Crossbow secure major funding for T-cell engager development
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-03-18 12:00 UTCUpdated 2026-03-18 15:07 UTC
rss
clinical_trialsbiotech_fundingdrug_developmentr_and_d
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Chinese biotech Excalipoint raised $69 million to advance its portfolio of next-generation T-cell engagers, marking one of the largest drug startup fundraises in China.
Entities
ExcalipointCrossbow Therapeutics
Score total
0.96
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Both companies recently closed large funding rounds within days of each other.
- T-cell engager therapies are gaining momentum as a promising immunotherapy approach.
- The capital influx enables rapid progression of clinical trials and R&D efforts.
Why it matters
- Significant funding rounds highlight investor confidence in T-cell engager therapies.
- Advances in T-cell engager portfolios could improve treatment options for cancer and other diseases.
- Funding supports clinical trials and pipeline expansion, accelerating drug development timelines.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- Excalipoint raised $69 million to advance next-generation T-cell engagers.
- Crossbow Therapeutics secured $77 million in Series B funding to support trials and pipeline expansion of T-cell engagers.
How sources frame it
- BioPharma Dive: neutral
- Fierce Biotech: neutral
All evidence
All evidence
Crossbow Therapeutics has successfully hit a $77 million series B round, which the biotech will use to fund a trial of its lead T-cell engager (TCE) and fill its quiver with mor...
Fierce Biotech · fiercebiotech.com · 2026-03-18 15:07 UTC
Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers
BioPharma Dive · biopharmadive.com · 2026-03-18 12:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (1)
- BioPharma Dive (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)